Company Overview - Metsera, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases [3] - The company was founded in 2022 and is based in New York City [3] - Metsera is advancing a portfolio of oral and injectable therapies targeting multiple therapeutic areas to meet the evolving needs of weight loss treatments [3] Upcoming Events - Whit Bernard, the CEO of Metsera, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, from 10:00 to 10:35 A.M. EDT [1] - A live webcast and replay of the presentation will be available on the company's website [2] Investor Relations - Metsera utilizes its website as a distribution channel for material information, with financial and important updates accessible through the Investors & News section [4] - Investors can sign up for email alerts to receive updates about the company [4]

Core Insights - Metsera, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases [3] - The CEO, Whit Bernard, will present at the Bank of America 2025 Global Healthcare Conference on May 14, 2025 [1] - A live webcast of the presentation will be available on Metsera's website [2] Company Overview - Metsera was founded in 2022 and is based in New York City [3] - The company is advancing a portfolio of oral and injectable therapies targeting obesity and metabolic diseases, including incretin and non-incretin therapies [3] - Metsera aims to address multiple therapeutic targets to meet the evolving needs of weight loss treatments [3] Investor Information - Metsera utilizes its website as a distribution channel for material information, which is accessible through the Investors & News section [4] - Investors can sign up for email alerts to receive updates about the company [4]